These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2325565)

  • 1. Role of 1,25(OH)2D in the genesis of secondary hyperparathyroidism of early renal failure and its use in the prevention of this abnormality.
    Massry SG
    Metabolism; 1990 Apr; 39(4 Suppl 1):13-7. PubMed ID: 2325565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency.
    Llach F; Massry SG
    J Clin Endocrinol Metab; 1985 Oct; 61(4):601-6. PubMed ID: 2993340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE; Mason NA
    Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.
    Lopez-Hilker S; Galceran T; Chan YL; Rapp N; Martin KJ; Slatopolsky E
    J Clin Invest; 1986 Oct; 78(4):1097-102. PubMed ID: 3760186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure.
    St John A; Thomas MB; Davies CP; Mullan B; Dick I; Hutchison B; van der Schaff A; Prince RL
    Nephron; 1992; 61(4):422-7. PubMed ID: 1501739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
    Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
    J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
    Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol.
    Rodriguez M; Martin-Malo A; Martinez ME; Torres A; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1055-62. PubMed ID: 1762306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D and hyperparathyroidism: the Lumleian Lecture 1981.
    Stanbury SW
    J R Coll Physicians Lond; 1981 Oct; 15(4):205-9, 212-7. PubMed ID: 6976436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration.
    Takamoto S; Onishi T; Morimoto S; Imanaka S; Tsuchiya H; Seino Y; Yokokawa T; Iida N; Kumahara Y
    Nephron; 1985; 40(3):286-91. PubMed ID: 3839293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal osteodystrophy and secondary hyperparathyroidism.
    Fukagawa M; Kazama JJ; Kurokawa K
    Nephrol Dial Transplant; 2002; 17 Suppl 10():2-5. PubMed ID: 12386262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we mismanaging calcium and phosphate metabolism in renal failure?
    Hsu CH
    Am J Kidney Dis; 1997 Apr; 29(4):641-9. PubMed ID: 9100059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.